NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Specialty and Branded Pharmaceuticals M&A update, 14–28 September 2026

A bi-weekly briefing on Specialty and Branded Pharmaceuticals covering public market moves, major disclosures and M&A activity from September 14–28, 2026, built for corporate development, IR and deal teams tracking sector-wide repricing and transaction signals.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Specialty and Branded Pharmaceuticals Sector Outlook — September 2026

Key figures

Sector Median Move
0.0%
23 covered names, close-to-close
S&P 500 Return
+0.8%
Same two-week window
Ascendis Pharma A/S (ASND)
-13.2%
Two-week share price return
GSK Myeloma Asset Deal
$750
Total potential consideration, up to

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS

Buyers Reach for Pipeline as Single Names Absorb the Repricing

This update covers what moved, what companies announced and what changed in the transaction record across Specialty and Branded Pharmaceuticals from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across 23 covered names, the two-week median move was 0.0% while the S&P 500 returned +0.8%, a flat average built from sharp individual swings. Declines concentrated in Premium-tier names, with Ascendis Pharma A/S falling -13.2% on disclosed news. GSK plc agreed to acquire an early-stage myeloma T-cell engager for up to $750 in potential consideration, signalling continued buyer appetite for pipeline over completed platforms. No completed sector transactions entered the record during the window.

Key findings

  • Flat sector median hides sharp single-name swings across the two-week window.
  • Premium-tier names bore the steepest declines, led by Ascendis and Alkermes.
  • GSK's early-stage myeloma deal shows buyers still pricing pipeline assets.
  • Legal and regulatory disclosures drove the period's largest single-day drops.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS

    This is the cover slide introducing the bi-weekly Specialty and Branded Pharmaceuticals industry events and M&A update for September 14–28, 2026.

    This bi-weekly update covers what changed, who moved and most likely why, what transacted, and what it means across Specialty and Branded Pharmaceuticals. We built this page to set the stage for the two weeks of evidence that follow.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS Buyers Reach for Pipeline as Single Names Absorb the Repricing This update covers what moved, what companies announced and what changed in the transaction record across Specialty and Branded Pharmaceuticals from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    A Flat Sector Average Hiding Heavy Single-Name Repricing

    This slide summarizes the two-week period's bottom line: a flat sector average masking sharp single-name repricing across 23 covered names.

    The sector median moved 0.0% over the two weeks, a flat headline that hides real divergence beneath it. Roughly half of the 23 covered names rose while others fell sharply, showing this was a stock-picker's period, not a sector-wide re-rating. We read this as a signal that company-specific news, not macro sentiment, drove the tape. So what: investors and operators should track name-level catalysts rather than sector averages going forward.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE A Flat Sector Average Hiding Heavy Single-Name Repricing The two-week period in one page · 23 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Half the Covered Set Rose and the Average Went Nowhere 11 of 23 covered names rose; the median move was 0.0%. The S&P 500 returned +0.8% over the same two-week period. 2 The Largest Declines Landed on Premium-Tier Names Ascendis Pharma A/S (ASND) returned -13.2% and Alkermes plc (ALKS) returned -12.4%. Both sit in the sector study's Premium tier, whose median is 5.1x forward EV/Revenue against a sector median of 2.7x. 3 Pipeline, Not Platforms, Drew the Period's Cheque GSK plc (GSK) agreed to acquire a trispecific T-cell engager for multiple myeloma, with total potential consideration of up to $750 million and Phase I trials slated for 2027. No completed sector transactions entered the record during the window. 4 Legal Overhang Did Visible Work at the Bottom of the Set Phathom Pharmaceuticals, Inc. (PHAT) returned -15.3% after a shareholder investigation announcement on September 16, with a new 12-month low reported the next day at $7.66. Unicycive Therapeutics, Inc. (UNCY) drew four separate class-action reminders in the window. +8.0% Best mover — RGC worst: PHAT -15.3% · 11 up / 11 down of 23 covered 0.0% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 4 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    Where the Two-Week Repricing Actually Landed

    This slide shows where the two-week repricing actually landed across covered names, benchmarked against the sector median and the S&P 500.

    Close-to-close moves over the window landed against a sector median of 0.0% and a S&P 500 return of +0.8%, so the index outperformed the median covered name. We set the materiality bar at ±9.4% on a sector-relative basis to separate signal from noise. Every move above that bar links back to a recorded filing or headline, so nothing here is guesswork. So what: the moves that cleared the bar are the ones worth underwriting into a view on the space.

    Everything on this page

    PUBLIC MARKET MOVERS Where the Two-Week Repricing Actually Landed Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median 0.0% · S&P 500 +0.8% · materiality bar ±9.4% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median 0.0% Phathom Pharmaceuticals, Inc. (PHAT) -15.3% Shares moved following the September 16 announcement of a shareholder investigation into Phathom; coverage the next day reported a new 12-month low, with the stock trading as low as $7.66 and last at $7.69. In the Discount tier, a legal overhang can reprice a brand faster than script trends can offset it. COMPANY-SPECIFIC Ascendis Pharma A/S (ASND) -13.2% The move appears to reflect the September 15 disclosures: Ascendis regains exclusive rights to TransCon technology products in metabolic and cardiovascular disease after a collaboration termination Taking a programme back in-house moves the spend onto the owner, and Premium-tier names are priced for that. COMPANY-SPECIFIC Journey Medical Corporation (DERM) -12.9% No notable in-window news was identified that clearly explains the move. Journey Medical Corporation (DERM) returned -12.9% against a 0.0% median across covered names. Core-tier small caps swing on modest flow, with the tier median at 2.2x forward EV/Revenue. UNEXPLAINED Regencell Bioscience Holdings Limited (RGC) +8.0% No notable in-window news was identified that clearly explains the move. Regencell Bioscience Holdings Limited (RGC) returned +8.0%, the largest gain in the covered set against a 0.0% median. Upside this period did not cluster around the sector's largest branded franchises. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Rights Reclaimed, a Regulatory Clock Started and Legal Files Opened

    This slide details the two-week period's highest-impact events, including a rights reversion, a regulatory review clock, and new legal disclosures.

    The period's most consequential events include a company regaining exclusive commercial rights, a regulatory review clock starting, and legal actions being disclosed against covered names. Each item on this page links directly to its source filing or article, so the trail is fully auditable. We read these as the catalysts most likely to explain the repricing seen on the prior pages. So what: these are the events worth diligencing first if you're assessing exposure to the space.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Rights Reclaimed, a Regulatory Clock Started and Legal Files Opened The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · 8-K · SEC EDGAR Ascendis takes back exclusive TransCon rights in metabolic and cardiovascular disease Regaining the rights puts the launch path, the manufacturing decision and the spend behind these programmes back with the owner. It also reopens label and indication expansion choices that were previously shared. Life-cycle management increasingly means owning an asset outright rather than partnering it. Sep 15 · 8-K · SEC EDGAR GSK agreed to acquire a trispecific T-cell engager for multiple myeloma A diversified innovator committing up to $750 million for a programme that has not yet entered the clinic says exclusivity gaps are being filled earlier on the development path. Phase I trials are slated for 2027. Strategics with cliffs to bridge are competing for science well ahead of commercial proof. Sep 15 · NEWS · Newsfile Corp Unicycive investors reminded of a November 2 lead plaintiff deadline in a securities case A live securities class action runs alongside the operating plan and can shape financing terms and partner conversations while it is open. Litigation exposure is now part of how the market prices smaller commercial-stage names. Sep 14 · NEWS · Business Wire FDA accepted Takeda's zasocitinib psoriasis application under Priority Review Priority Review puts a potential oral entrant into a heavily managed category where formulary tier position and prior authorisation decide how fast uptake actually builds. Regulatory timing remains the most direct lever on a branded franchise's forward revenue. Sep 14 · NEWS · GlobeNewsWire A second firm reminded Unicycive shareholders of the November 2 class action deadline Repeated notices on the same claim period keep the matter in front of investors for longer, which extends the period of uncertainty around the name. Sustained legal noise widens the valuation gap between similar-stage assets. Sep 14 · NEWS · GlobeNewsWire Class action filed against Unicycive covering purchases from late 2025 into mid-2026 The defined claim period ties the complaint to a specific stretch of company disclosure, which is the detail acquirers and partners will test first. Diligence on smaller branded names now starts with the disclosure record, not the label.

  5. 05
    M&A & STRATEGIC ACTIVITY

    GSK Agrees to Buy a Myeloma T-Cell Engager Before Phase I Starts

    This slide covers the period's sole agreed M&A transaction: GSK's acquisition of a pre-clinical myeloma T-cell engager against a backdrop of 40 recorded precedent deals.

    GSK agreed to acquire a trispecific T-cell engager for multiple myeloma before Phase I trials even start, with total potential consideration of up to $750. This sits against a precedent set of 40 recorded deals in the space, giving the market a fresh early-stage reference point. We read this as continued buyer appetite for pipeline assets rather than completed platforms. So what: expect further early-stage bolt-on activity as large caps compete for differentiated mechanisms ahead of clinical readouts.

    Everything on this page

    M&A & STRATEGIC ACTIVITY GSK Agrees to Buy a Myeloma T-Cell Engager Before Phase I Starts September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 15 · GSK plc (GSK) GSK plc (GSK) agreed to acquire a trispecific T-cell engager for multiple myeloma from a privately held developer The structure — a capped total with the programme slated to enter Phase I in 2027 — is consistent with a buyer paying for future exclusivity rather than current revenue. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What This Two-Week Period Changes for You

    This slide translates the two-week period's evidence into implications for operators, acquirers, and advisors.

    For operators, the moves that had a documented cause tracked fundamentals like net price realization and script trends, not sentiment. For acquirers, GSK's early-stage myeloma agreement adds a fresh reference point for milestone-weighted pricing on pre-clinical assets. For advisors, the period's evidence argues for underwriting at the asset level rather than the entity level. So what: each audience has a specific, actionable read from this window, not just a sector-wide observation.

    Everything on this page

    WHAT IT MEANS What This Two-Week Period Changes for You The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 2.7x 25 companies in the study 3 valuation tiers Standing thesis: Specialty and Branded Pharmaceuticals splits three ways: pipelines, hybrid portfolios and diversified platforms FOR OWNERS & OPERATORS Revenue Quality Carried the Names That Had a Record Behind Them Companies in the sector traded in both directions and the median move was 0.0%. The moves with a documented cause tracked what operators actually run: net price realisation after gross-to-net, TRx and NRx script trends FOR ACQUIRERS The Reference Set Gains an Asset-Level, Pre-Clinical Comparison Point GSK's agreement for a myeloma T-cell engager at up to $750 million gives the record a fresh milestone-weighted reference for early assets. Ascendis regaining TransCon rights shows programmes returning to owners rather than moving to buyers. FOR ADVISORS Lead with the Asset, Not the Entity The period's evidence is asset-level: one agreed programme acquisition, one rights reversion, a Priority Review acceptance and a Phase 2 start.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This slide explains the sources and methodology behind the update, including how figures are sourced and verified.

    Every figure in this update links back to the filing, press release, or market data point it was drawn from. We rank sources in a fixed reliability order — SEC filings first, then press releases, then established outlets — and never draw on video or social platforms. This discipline is what lets us make calibrated, evidence-linked reads rather than speculative calls. So what: you can trust every number in this deck traces to a primary, checkable source.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Specialty and Branded Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T173811Z_551_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: sec.gov · newsfilecorp.com · businesswire.com · globenewswire.com · prnewswire.com

Sources and methodology

This update covers Specialty and Branded Pharmaceuticals over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 23 listed companies whose core business is Specialty and Branded Pharmaceuticals under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Achieve Life Sciences, Inc. (ACHV), Akebia Therapeutics, Inc. (AKBA), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), Ardelyx, Inc. (ARDX), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), Journey Medical Corporation (DERM), Evolus, Inc. (EOLS), GSK plc (GSK), Indivior Pharmaceuticals Inc (INDV), Novartis AG (NVS), OPKO Health, Inc. (OPK), Pacira BioSciences, Inc. (PCRX), Phathom Pharmaceuticals, Inc. (PHAT), Regencell Bioscience Holdings Limited (RGC), Sol-Gel Technologies Ltd. (SLGL), Takeda Pharmaceutical Company Limited (TAK), Theravance Biopharma Inc (TBPH), Trevi Therapeutics, Inc. (TRVI), Unicycive Therapeutics, Inc. (UNCY), Zoetis Inc. (ZTS), Zevra Therapeutics, Inc. (ZVRA). 2 names below the floor were excluded from the statistics: HRTX, SCLX.

Window and company universe

This update covers Specialty and Branded Pharmaceuticals over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 23 listed companies whose core business is Specialty and Branded Pharmaceuticals under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Achieve Life Sciences, Inc. (ACHV), Akebia Therapeutics, Inc. (AKBA), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), Ardelyx, Inc. (ARDX), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), Journey Medical Corporation (DERM), Evolus, Inc. (EOLS), GSK plc (GSK), Indivior Pharmaceuticals Inc (INDV), Novartis AG (NVS), OPKO Health, Inc. (OPK), Pacira BioSciences, Inc. (PCRX), Phathom Pharmaceuticals, Inc. (PHAT), Regencell Bioscience Holdings Limited (RGC), Sol-Gel Technologies Ltd. (SLGL), Takeda Pharmaceutical Company Limited (TAK), Theravance Biopharma Inc (TBPH), Trevi Therapeutics, Inc. (TRVI), Unicycive Therapeutics, Inc. (UNCY), Zoetis Inc. (ZTS), Zevra Therapeutics, Inc. (ZVRA). 2 names below the floor were excluded from the statistics: HRTX, SCLX.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Specialty and Branded Pharmaceuticals?

Company valuation reports run the same method against a single business — public or private.